The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary results of a phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology (NSCLC-NS) with disease progression after a bevacizumab (bev) containing therapy.
Thomas E. Stinchcombe
Research Funding - GlaxoSmithKline
Jared Weiss
No relevant relationships to disclose
Liza Cosca Villaruz
No relevant relationships to disclose
Anastasia Ivanova
No relevant relationships to disclose
Juneko E. Grilley-Olson
Research Funding - Bayer; GlaxoSmithKline; Kyowa Hakko Kirin; Novartis; ZIOPHARM Oncology
Nirav Suresh Dhruva
No relevant relationships to disclose
Mark A. Socinski
No relevant relationships to disclose